Skip to main content
Top
Published in: Journal of Neuroinflammation 1/2012

Open Access 01-12-2012 | Research

Naloxone inhibits immune cell function by suppressing superoxide production through a direct interaction with gp91 phox subunit of NADPH oxidase

Authors: Qingshan Wang, Hui Zhou, Huiming Gao, Shih-Heng Chen, Chun-Hsien Chu, Belinda Wilson, Jau-Shyong Hong

Published in: Journal of Neuroinflammation | Issue 1/2012

Login to get access

Abstract

Background

Both (-) and (+)-naloxone attenuate inflammation-mediated neurodegeneration by inhibition of microglial activation through superoxide reduction in an opioid receptor-independent manner. Multiple lines of evidence have documented a pivotal role of overactivated NADPH oxidase (NOX2) in inflammation-mediated neurodegeneration. We hypothesized that NOX2 might be a novel action site of naloxone to mediate its anti-inflammatory actions.

Methods

Inhibition of NOX-2-derived superoxide by (-) and (+)-naloxone was measured in lipopolysaccharide (LPS)-treated midbrain neuron-glia cultures and phorbol myristate acetate (PMA)-stimulated neutrophil membranes by measuring the superoxide dismutase (SOD)-inhibitable reduction of tetrazolium salt (WST-1) or ferricytochrome c. Further, various ligand (3H-naloxone) binding assays were performed in wild type and gp91 phox-/- neutrophils and transfected COS-7 and HEK293 cells. The translocation of cytosolic subunit p47 phox to plasma membrane was assessed by western blot.

Results

Both (-) and (+)-naloxone equally inhibited LPS- and PMA-induced superoxide production with an IC50 of 1.96 and 2.52 μM, respectively. Competitive binding of 3H-naloxone with cold (-) and (+)-naloxone in microglia showed equal potency with an IC50 of 2.73 and 1.57 μM, respectively. 3H-Naloxone binding was elevated in COS-7 and HEK293 cells transfected with gp91 phox ; in contrast, reduced 3H-naloxone binding was found in neutrophils deficient in gp91 phox or in the presence of a NOX2 inhibitor. The specificity and an increase in binding capacity of 3H-naloxone were further demonstrated by 1) an immunoprecipitation study using gp91 phox antibody, and 2) activation of NOX2 by PMA. Finally, western blot studies showed that naloxone suppressed translocation of the cytosolic subunit p47 phox to the membrane, leading to NOX2 inactivation.

Conclusions

Strong evidence is provided indicating that NOX2 is a non-opioid novel binding site for naloxone, which is critical in mediating its inhibitory effect on microglia overactivation and superoxide production.
Literature
1.
go back to reference Gao HM, Hong JS: Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 2008, 29:357–365.CrossRefPubMedPubMedCentral Gao HM, Hong JS: Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 2008, 29:357–365.CrossRefPubMedPubMedCentral
2.
go back to reference Nelson PT, Soma LA, Lavi E: Microglia in diseases of the central nervous system. Ann Med 2002, 34:491–500.CrossRefPubMed Nelson PT, Soma LA, Lavi E: Microglia in diseases of the central nervous system. Ann Med 2002, 34:491–500.CrossRefPubMed
3.
go back to reference Liu B, Du L, Hong JS: Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther 2000, 293:607–617.PubMed Liu B, Du L, Hong JS: Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther 2000, 293:607–617.PubMed
4.
go back to reference Liu B, Du L, Kong LY, Hudson PM, Wilson BC, Chang RC, Abel HH, Hong JS: Reduction by naloxone of lipopolysaccharide-induced neurotoxicity in mouse cortical neuron-glia co-cultures. Neuroscience 2000, 97:749–756.CrossRefPubMed Liu B, Du L, Kong LY, Hudson PM, Wilson BC, Chang RC, Abel HH, Hong JS: Reduction by naloxone of lipopolysaccharide-induced neurotoxicity in mouse cortical neuron-glia co-cultures. Neuroscience 2000, 97:749–756.CrossRefPubMed
5.
go back to reference Liu B, Jiang JW, Wilson BC, Du L, Yang SN, Wang JY, Wu GC, Cao XD, Hong JS: Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide. J Pharmacol Exp Ther 2000, 295:125–132.PubMed Liu B, Jiang JW, Wilson BC, Du L, Yang SN, Wang JY, Wu GC, Cao XD, Hong JS: Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide. J Pharmacol Exp Ther 2000, 295:125–132.PubMed
6.
go back to reference Liu Y, Qin L, Wilson BC, An L, Hong JS, Liu B: Inhibition by naloxone stereoisomers of beta-amyloid peptide (1–42)-induced superoxide production in microglia and degeneration of cortical and mesencephalic neurons. J Pharmacol Exp Ther 2002, 302:1212–1219.CrossRefPubMed Liu Y, Qin L, Wilson BC, An L, Hong JS, Liu B: Inhibition by naloxone stereoisomers of beta-amyloid peptide (1–42)-induced superoxide production in microglia and degeneration of cortical and mesencephalic neurons. J Pharmacol Exp Ther 2002, 302:1212–1219.CrossRefPubMed
7.
go back to reference Qin L, Block ML, Liu Y, Bienstock RJ, Pei Z, Zhang W, Wu X, Wilson B, Burka T, Hong JS: Microglial NADPH oxidase is a novel target for femtomolar neuroprotection against oxidative stress. FASEB J 2005, 19:550–557.CrossRefPubMed Qin L, Block ML, Liu Y, Bienstock RJ, Pei Z, Zhang W, Wu X, Wilson B, Burka T, Hong JS: Microglial NADPH oxidase is a novel target for femtomolar neuroprotection against oxidative stress. FASEB J 2005, 19:550–557.CrossRefPubMed
8.
go back to reference Hutchinson MR, Zhang Y, Brown K, Coats BD, Shridhar M, Sholar PW, Patel SJ, Crysdale NY, Harrison JA, Maier SF, et al.: Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci 2008, 28:20–29.CrossRefPubMedPubMedCentral Hutchinson MR, Zhang Y, Brown K, Coats BD, Shridhar M, Sholar PW, Patel SJ, Crysdale NY, Harrison JA, Maier SF, et al.: Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci 2008, 28:20–29.CrossRefPubMedPubMedCentral
9.
go back to reference Hutchinson MR, Zhang Y, Shridhar M, Evans JH, Buchanan MM, Zhao TX, Slivka PF, Coats BD, Rezvani N, Wieseler J, Hughes TS, Landgraf KE, Chan S, Fong S, Phipps S, Falke JJ, Leinwand LA, Maier SF, Yin H, Rice KC, Watkins LR: Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun 2010, 24:83–95.CrossRefPubMed Hutchinson MR, Zhang Y, Shridhar M, Evans JH, Buchanan MM, Zhao TX, Slivka PF, Coats BD, Rezvani N, Wieseler J, Hughes TS, Landgraf KE, Chan S, Fong S, Phipps S, Falke JJ, Leinwand LA, Maier SF, Yin H, Rice KC, Watkins LR: Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun 2010, 24:83–95.CrossRefPubMed
10.
go back to reference Wang HY, Burns LH: Naloxone's pentapeptide binding site on filamin A blocks Mu opioid receptor-Gs coupling and CREB activation of acute morphine. PLoS One 2009, 4:e4282.CrossRefPubMedPubMedCentral Wang HY, Burns LH: Naloxone's pentapeptide binding site on filamin A blocks Mu opioid receptor-Gs coupling and CREB activation of acute morphine. PLoS One 2009, 4:e4282.CrossRefPubMedPubMedCentral
11.
go back to reference Yang L, Li F, Ge W, Mi C, Wang R, Sun R: Protective effects of naloxone in two-hit seizure model. Epilepsia 2010, 51:344–353.CrossRefPubMed Yang L, Li F, Ge W, Mi C, Wang R, Sun R: Protective effects of naloxone in two-hit seizure model. Epilepsia 2010, 51:344–353.CrossRefPubMed
12.
go back to reference Liu SL, Li YH, Shi GY, Chen YH, Huang CW, Hong JS, Wu HL: A novel inhibitory effect of naloxone on macrophage activation and atherosclerosis formation in mice. J Am Coll Cardiol 2006, 48:1871–1879.CrossRefPubMed Liu SL, Li YH, Shi GY, Chen YH, Huang CW, Hong JS, Wu HL: A novel inhibitory effect of naloxone on macrophage activation and atherosclerosis formation in mice. J Am Coll Cardiol 2006, 48:1871–1879.CrossRefPubMed
13.
go back to reference Gao HM, Hong JS, Zhang W, Liu B: Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 2002, 22:782–790.PubMed Gao HM, Hong JS, Zhang W, Liu B: Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 2002, 22:782–790.PubMed
14.
go back to reference Luo Y, Dorf ME: Isolation of mouse neutrophils. Curr Protoc Immunol 2001,3(3):20.PubMed Luo Y, Dorf ME: Isolation of mouse neutrophils. Curr Protoc Immunol 2001,3(3):20.PubMed
15.
go back to reference Herren T, Burke TA, Jardi M, Felez J, Plow EF: Regulation of plasminogen binding to neutrophils. Blood 2001, 97:1070–1078.CrossRefPubMed Herren T, Burke TA, Jardi M, Felez J, Plow EF: Regulation of plasminogen binding to neutrophils. Blood 2001, 97:1070–1078.CrossRefPubMed
16.
go back to reference Zhou H, Zhang F, Chen SH, Zhang D, Wilson B, Hong JS, Gao HM: Rotenone activates phagocyte NADPH oxidase by binding to its membrane subunit gp91(phox). Free Radic BiolMed 2012, 52:303–313.CrossRef Zhou H, Zhang F, Chen SH, Zhang D, Wilson B, Hong JS, Gao HM: Rotenone activates phagocyte NADPH oxidase by binding to its membrane subunit gp91(phox). Free Radic BiolMed 2012, 52:303–313.CrossRef
17.
go back to reference Qian L, Wei SJ, Zhang D, Hu X, Xu Z, Wilson B, El-Benna J, Hong JS, Flood PM: Potent anti-inflammatory and neuroprotective effects of TGF-beta1 are mediated through the inhibition of ERK and p47phox-Ser345 phosphorylation and translocation in microglia. J Immunol 2008, 181:660–668.CrossRefPubMedPubMedCentral Qian L, Wei SJ, Zhang D, Hu X, Xu Z, Wilson B, El-Benna J, Hong JS, Flood PM: Potent anti-inflammatory and neuroprotective effects of TGF-beta1 are mediated through the inhibition of ERK and p47phox-Ser345 phosphorylation and translocation in microglia. J Immunol 2008, 181:660–668.CrossRefPubMedPubMedCentral
18.
go back to reference Simpkins CO, Alailima ST, Tate EA: Inhibition by naloxone of neutrophil superoxide release: a potentially useful antiinflammatory effect. Circ Shock 1986, 20:181–191.PubMed Simpkins CO, Alailima ST, Tate EA: Inhibition by naloxone of neutrophil superoxide release: a potentially useful antiinflammatory effect. Circ Shock 1986, 20:181–191.PubMed
19.
go back to reference Bedard K, Krause KH: The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007, 87:245–313.CrossRefPubMed Bedard K, Krause KH: The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007, 87:245–313.CrossRefPubMed
20.
go back to reference Yu L, Zhen L, Dinauer MC: Biosynthesis of the phagocyte NADPH oxidase cytochrome b558. Role of heme incorporation and heterodimer formation in maturation and stability of gp91phox and p22phox subunits. J Biol Chem 1997, 272:27288–27294.CrossRefPubMed Yu L, Zhen L, Dinauer MC: Biosynthesis of the phagocyte NADPH oxidase cytochrome b558. Role of heme incorporation and heterodimer formation in maturation and stability of gp91phox and p22phox subunits. J Biol Chem 1997, 272:27288–27294.CrossRefPubMed
21.
go back to reference Caldiroli E, Leoni O, Cattaneo S, Rasini E, Marino V, Tosetto C, Mazzone A, Fietta AM, Lecchini S, Frigo GM: Neutrophil function and opioid receptor expression on leucocytes during chronic naltrexone treatment in humans. Pharmacol Res 1999, 40:153–158.CrossRefPubMed Caldiroli E, Leoni O, Cattaneo S, Rasini E, Marino V, Tosetto C, Mazzone A, Fietta AM, Lecchini S, Frigo GM: Neutrophil function and opioid receptor expression on leucocytes during chronic naltrexone treatment in humans. Pharmacol Res 1999, 40:153–158.CrossRefPubMed
22.
go back to reference Doussiere J, Gaillard J, Vignais PV: The heme component of the neutrophil NADPH oxidase complex is a target for aryliodonium compounds. Biochemistry 1999, 38:3694–3703.CrossRefPubMed Doussiere J, Gaillard J, Vignais PV: The heme component of the neutrophil NADPH oxidase complex is a target for aryliodonium compounds. Biochemistry 1999, 38:3694–3703.CrossRefPubMed
23.
go back to reference O'Donnell BV, Tew DG, Jones OT, England PJ: Studies on the inhibitory mechanism of iodonium compounds with special reference to neutrophil NADPH oxidase. Biochem J 1993, 290:41–49.CrossRefPubMedPubMedCentral O'Donnell BV, Tew DG, Jones OT, England PJ: Studies on the inhibitory mechanism of iodonium compounds with special reference to neutrophil NADPH oxidase. Biochem J 1993, 290:41–49.CrossRefPubMedPubMedCentral
24.
25.
go back to reference Liu B, Hong JS: Neuroprotective effect of naloxone in inflammation-mediated dopaminergic neurodegeneration. Dissociation from the involvement of opioid receptors. Methods Mol Med 2003, 79:43–54.PubMed Liu B, Hong JS: Neuroprotective effect of naloxone in inflammation-mediated dopaminergic neurodegeneration. Dissociation from the involvement of opioid receptors. Methods Mol Med 2003, 79:43–54.PubMed
26.
go back to reference Simpkins CO, Ives N, Tate E, Johnson M: Naloxone inhibits superoxide release from human neutrophils. Life Sci 1985, 37:1381–1386.CrossRefPubMed Simpkins CO, Ives N, Tate E, Johnson M: Naloxone inhibits superoxide release from human neutrophils. Life Sci 1985, 37:1381–1386.CrossRefPubMed
27.
go back to reference Price M, Gistrak MA, Itzhak Y, Hahn EF, Pasternak GW: Receptor binding of [3H]naloxone benzoylhydrazone: a reversible kappa and slowly dissociable mu opiate. Mol Pharmacol 1989, 35:67–74.PubMed Price M, Gistrak MA, Itzhak Y, Hahn EF, Pasternak GW: Receptor binding of [3H]naloxone benzoylhydrazone: a reversible kappa and slowly dissociable mu opiate. Mol Pharmacol 1989, 35:67–74.PubMed
28.
go back to reference Tepperman FS, Hirst M, Smith P: Brain and serum levels of naloxone following peripheral administration. Life Sci 1983, 33:1091–1096.CrossRefPubMed Tepperman FS, Hirst M, Smith P: Brain and serum levels of naloxone following peripheral administration. Life Sci 1983, 33:1091–1096.CrossRefPubMed
29.
go back to reference Suzuki T, Ohmuro A, Miyata M, Furuishi T, Hidaka S, Kugawa F, Fukami T, Tomono K: Involvement of an influx transporter in the blood-brain barrier transport of naloxone. Biopharm Drug Dispos 2010, 31:243–252.PubMed Suzuki T, Ohmuro A, Miyata M, Furuishi T, Hidaka S, Kugawa F, Fukami T, Tomono K: Involvement of an influx transporter in the blood-brain barrier transport of naloxone. Biopharm Drug Dispos 2010, 31:243–252.PubMed
30.
go back to reference Curtis MT, Lefer AM: Protective actions of naloxone in hemorrhagic shock. Am J Physiol 1980, 239:H416-H421.PubMed Curtis MT, Lefer AM: Protective actions of naloxone in hemorrhagic shock. Am J Physiol 1980, 239:H416-H421.PubMed
31.
go back to reference Carratu MR, Mitolo-Chieppa D: Inhibition of ionic currents in frog node of Ranvier treated with naloxone. Br J Pharmacol 1982, 77:115–119.CrossRefPubMedCentral Carratu MR, Mitolo-Chieppa D: Inhibition of ionic currents in frog node of Ranvier treated with naloxone. Br J Pharmacol 1982, 77:115–119.CrossRefPubMedCentral
32.
go back to reference Gutierrez R: Effects of naloxone on membrane potential of identified neurons of Helix aspersa. Comp Biochem Physiol C 1992, 101:425–431.CrossRefPubMed Gutierrez R: Effects of naloxone on membrane potential of identified neurons of Helix aspersa. Comp Biochem Physiol C 1992, 101:425–431.CrossRefPubMed
33.
go back to reference Watkins LR, Hutchinson MR, Johnston IN, Maier SF: Glia: novel counter-regulators of opioid analgesia. Trends Neurosci 2005, 28:661–669.CrossRefPubMed Watkins LR, Hutchinson MR, Johnston IN, Maier SF: Glia: novel counter-regulators of opioid analgesia. Trends Neurosci 2005, 28:661–669.CrossRefPubMed
34.
go back to reference Johnston IN, Milligan ED, Wieseler-Frank J, Frank MG, Zapata V, Campisi J, Langer S, Martin D, Green P, Fleshner M, Leinwand L, Maier SF, Watkins LR: A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J Neurosci 2004, 24:7353–7365.CrossRefPubMed Johnston IN, Milligan ED, Wieseler-Frank J, Frank MG, Zapata V, Campisi J, Langer S, Martin D, Green P, Fleshner M, Leinwand L, Maier SF, Watkins LR: A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J Neurosci 2004, 24:7353–7365.CrossRefPubMed
35.
go back to reference Muscoli C, Doyle T, Dagostino C, Bryant L, Chen Z, Watkins LR, Ryerse J, Bieberich E, Neumman W, Salvemini D: Counter-regulation of opioid analgesia by glial-derived bioactive sphingolipids. J Neurosci 2010, 30:15400–15408.CrossRefPubMedPubMedCentral Muscoli C, Doyle T, Dagostino C, Bryant L, Chen Z, Watkins LR, Ryerse J, Bieberich E, Neumman W, Salvemini D: Counter-regulation of opioid analgesia by glial-derived bioactive sphingolipids. J Neurosci 2010, 30:15400–15408.CrossRefPubMedPubMedCentral
36.
go back to reference Hutchinson MR, Bland ST, Johnson KW, Rice KC, Maier SF, Watkins LR: Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. ScientificWorldJournal 2007, 7:98–111.CrossRefPubMed Hutchinson MR, Bland ST, Johnson KW, Rice KC, Maier SF, Watkins LR: Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. ScientificWorldJournal 2007, 7:98–111.CrossRefPubMed
37.
go back to reference Lewis SS, Hutchinson MR, Rezvani N, Loram LC, Zhang Y, Maier SF, Rice KC, Watkins LR: Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1beta. Neuroscience 2010, 165:569–583.CrossRefPubMedPubMedCentral Lewis SS, Hutchinson MR, Rezvani N, Loram LC, Zhang Y, Maier SF, Rice KC, Watkins LR: Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1beta. Neuroscience 2010, 165:569–583.CrossRefPubMedPubMedCentral
38.
go back to reference Hutchinson MR, Zhang Y, Shridhar M, Evans JH, Buchanan MM, Zhao TX, Slivka PF, Coats BD, Rezvani N, Wieseler J, Hughes TS, Landgraf KE, Chan S, Fong S, Phipps S, Falke JJ, Leinwand LA, Maier SF, Yin H, Rice KC, Watkins LR: Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain, Behav Immun 2010, 24:83–95.CrossRef Hutchinson MR, Zhang Y, Shridhar M, Evans JH, Buchanan MM, Zhao TX, Slivka PF, Coats BD, Rezvani N, Wieseler J, Hughes TS, Landgraf KE, Chan S, Fong S, Phipps S, Falke JJ, Leinwand LA, Maier SF, Yin H, Rice KC, Watkins LR: Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain, Behav Immun 2010, 24:83–95.CrossRef
39.
go back to reference Liu L, Coller JK, Watkins LR, Somogyi AA, Hutchinson MR: Naloxone-precipitated morphine withdrawal behavior and brain IL-1beta expression: comparison of different mouse strains. Brain, Behav Immun 2011, 25:1223–1232.CrossRef Liu L, Coller JK, Watkins LR, Somogyi AA, Hutchinson MR: Naloxone-precipitated morphine withdrawal behavior and brain IL-1beta expression: comparison of different mouse strains. Brain, Behav Immun 2011, 25:1223–1232.CrossRef
40.
go back to reference Watkins LR, Hutchinson MR, Rice KC, Maier SF: The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends in pharmacological sciences 2009, 30:581–591.CrossRefPubMedPubMedCentral Watkins LR, Hutchinson MR, Rice KC, Maier SF: The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends in pharmacological sciences 2009, 30:581–591.CrossRefPubMedPubMedCentral
41.
go back to reference Qin L, Block ML, Liu Y, Bienstock RJ, Pei Z, Zhang W, Wu X, Wilson B, Burka T, Hong JS: Microglial NADPH oxidase is a novel target for femtomolar neuroprotection against oxidative stress. FASEB J 2005, 19:550–557.CrossRefPubMed Qin L, Block ML, Liu Y, Bienstock RJ, Pei Z, Zhang W, Wu X, Wilson B, Burka T, Hong JS: Microglial NADPH oxidase is a novel target for femtomolar neuroprotection against oxidative stress. FASEB J 2005, 19:550–557.CrossRefPubMed
42.
go back to reference Qian L, Tan KS, Wei SJ, Wu HM, Xu Z, Wilson B, Lu RB, Hong JS, Flood PM: Microglia-mediated neurotoxicity is inhibited by morphine through an opioid receptor-independent reduction of NADPH oxidase activity. J Immunol 2007, 179:1198–1209.CrossRefPubMed Qian L, Tan KS, Wei SJ, Wu HM, Xu Z, Wilson B, Lu RB, Hong JS, Flood PM: Microglia-mediated neurotoxicity is inhibited by morphine through an opioid receptor-independent reduction of NADPH oxidase activity. J Immunol 2007, 179:1198–1209.CrossRefPubMed
43.
go back to reference Li G, Cui G, Tzeng NS, Wei SJ, Wang T, Block ML, Hong JS: Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage. FASEB J 2005, 19:489–496.CrossRefPubMed Li G, Cui G, Tzeng NS, Wei SJ, Wang T, Block ML, Hong JS: Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage. FASEB J 2005, 19:489–496.CrossRefPubMed
44.
go back to reference Zhang W, Wang T, Qin L, Gao HM, Wilson B, Ali SF, Hong JS, Liu B: Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase. FASEB J 2004, 18:589–591. Zhang W, Wang T, Qin L, Gao HM, Wilson B, Ali SF, Hong JS, Liu B: Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase. FASEB J 2004, 18:589–591.
45.
go back to reference Zhang W, Qin L, Wang T, Wei SJ, Gao HM, Liu J, Wilson B, Liu B, Kim HC, Hong JS: 3-hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity. FASEB J 2005, 19:395–397.PubMed Zhang W, Qin L, Wang T, Wei SJ, Gao HM, Liu J, Wilson B, Liu B, Kim HC, Hong JS: 3-hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity. FASEB J 2005, 19:395–397.PubMed
46.
go back to reference Zhang W, Shin EJ, Wang T, Lee PH, Pang H, Wie MB, Kim WK, Kim SJ, Huang WH, Wang Y, Zhang W, Hong JS, Kim HC: 3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro. FASEB J 2006, 20:2496–2511.CrossRefPubMed Zhang W, Shin EJ, Wang T, Lee PH, Pang H, Wie MB, Kim WK, Kim SJ, Huang WH, Wang Y, Zhang W, Hong JS, Kim HC: 3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro. FASEB J 2006, 20:2496–2511.CrossRefPubMed
47.
go back to reference Qian L, Xu Z, Zhang W, Wilson B, Hong JS, Flood PM: Sinomenine, a natural dextrorotatory morphinan analog, is anti-inflammatory and neuroprotective through inhibition of microglial NADPH oxidase. J Neuroinflammation 2007, 4:23.CrossRefPubMedPubMedCentral Qian L, Xu Z, Zhang W, Wilson B, Hong JS, Flood PM: Sinomenine, a natural dextrorotatory morphinan analog, is anti-inflammatory and neuroprotective through inhibition of microglial NADPH oxidase. J Neuroinflammation 2007, 4:23.CrossRefPubMedPubMedCentral
Metadata
Title
Naloxone inhibits immune cell function by suppressing superoxide production through a direct interaction with gp91 phox subunit of NADPH oxidase
Authors
Qingshan Wang
Hui Zhou
Huiming Gao
Shih-Heng Chen
Chun-Hsien Chu
Belinda Wilson
Jau-Shyong Hong
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2012
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/1742-2094-9-32

Other articles of this Issue 1/2012

Journal of Neuroinflammation 1/2012 Go to the issue